FXR
El receptor X de farnesoide (FXR) es un receptor nuclear que desempeña un papel clave en la regulación de la homeostasis de los ácidos biliares, el metabolismo de los lípidos y la regulación de la glucosa. El FXR es un objetivo terapéutico potencial para el tratamiento de enfermedades hepáticas, trastornos metabólicos y enfermedades cardiovasculares. Los inhibidores del FXR pueden modular estas vías, ofreciendo información sobre los mecanismos de las enfermedades y las estrategias terapéuticas. En CymitQuimica, ofrecemos una gama de inhibidores del FXR para apoyar su investigación en hepatología, metabolismo y desarrollo de fármacos.
Se han encontrado 62 productos de "FXR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Fexarine
CAS:Fexarine is a potent, selective agonist of farnesoid X receptor.Fórmula:C31H31NO5Forma y color:SolidPeso molecular:497.58ST-1892
CAS:ST-1892 is a soluble partial FXR agonist.Fórmula:C16H12N2O3Pureza:98%Forma y color:SolidPeso molecular:280.28LY367385
CAS:LY367385 is a highly effective and selective mGluR1a antagonist.Fórmula:C10H11NO4Pureza:98%Forma y color:SolidPeso molecular:209.2HPG1860
CAS:HPG1860, an agonist of the farnesoid X receptor (FXR), induces luminescence in reporter gene assays utilizing HEK293T cells expressing human FXR, with an EC50 value of 18 nM. In vivo studies demonstrate that HPG1860 (administered at 1, 3, or 10 mg/kg daily) reduces serum alanine aminotransferase (ALT) and total cholesterol levels in a mouse model of non-alcoholic steatohepatitis (NASH), which was induced by a high-fat diet and carbon tetrachloride (CCl4). Additionally, this compound decreases hepatic inflammation, fat levels, and fibrosis.Fórmula:C27H26Cl2N4O4SForma y color:SolidPeso molecular:573.49FXR agonist 4
FXR agonist 4: EC50 of 1.05μM, treats hyperlipidemia, steatosis, insulin resistance, inflammation in DIO mice, for NAFLD research.Fórmula:C21H28ClN3OForma y color:SolidPeso molecular:373.92PX20606
CAS:PX20606 is an orally active farnesoid X receptor (FXR) agonist, demonstrating EC50 values of 220 nM (mFXR) and 50 nM (hFXR) in Gal4-FXR assays. It induces the expression of the tumor suppressor gene NDRG2 and inhibits tumor growth and metastasis in a mouse HCC model. Additionally, PX20606 exhibits hepatoprotective properties.
Fórmula:C29H22Cl3NO4Forma y color:SolidPeso molecular:554.85EDP-305
CAS:EDP-305, an oral FXR agonist, has EC50s of 34 nM/8 nM in CHO/HEK cells, aids in PBC and NASH research with antifibrotic properties.Fórmula:C36H58N2O5SForma y color:SolidPeso molecular:630.92BMS-986318
CAS:BMS-986318: potent FXR agonist, EC50=53/350 nM, good ADME, effective in liver disease models, for nonalcoholic steatohepatitis research.Fórmula:C30H23Cl2F3N4O3Forma y color:SolidPeso molecular:615.43GSK2324
CAS:GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis.Fórmula:C29H22Cl2N2O4Pureza:98.09% - 99.02%Forma y color:SolidPeso molecular:533.4FXR antagonist 1
CAS:"Oral FXR antagonist 1 selectively blocks intestinal FXR, with IC50 of 2.1 μM, aiding in NASH research by improving liver health."Fórmula:C36H59NO5Forma y color:SolidPeso molecular:585.86Chenodeoxycholic Acid 24-Acyl-β-D-Glucuronide
CAS:Chenodeoxycholic acid 24-acyl-β-D-glucuronide (CDCA-24G), a metabolite of CDCA, is synthesized from CDCA via the action of the UDP-glucuronosyltransferase (UG UT) isoform UGT1A3.Fórmula:C30H48O10Forma y color:SolidPeso molecular:568.7Chenodeoxycholic Acid 3-Glucuronide
CAS:Chenodeoxycholic acid 3-glucuronide (CDCA-3G), a metabolite of Chenodeoxycholic acid (CDCA), is synthesized in human liver microsomes.Fórmula:C30H48O10Forma y color:SolidPeso molecular:568.7GSK-8062
CAS:GSK-8062 is an agonist of farnesoid X receptor (FXR).Fórmula:C30H23Cl2NO4Pureza:98%Forma y color:SolidPeso molecular:532.41Omesdafexor
CAS:Omesdafexor is an FXR agonist that can be used to study diseases caused by liver disease or metabolic inflammation.Fórmula:C34H43N3O3Forma y color:SolidPeso molecular:541.72Lecufexor
CAS:Lecufexor is an agonist of the farnesoid X receptor (FXR).Fórmula:C32H21Cl3N2O5Forma y color:SolidPeso molecular:619.88BAR-2227
CAS:BAR-2227 (compound 3a) functions as an FXR agonist and a LIFR inhibitor. It is utilized in the study of liver fibrosis and inflammation.Fórmula:C24H17Cl2NO4Forma y color:SolidPeso molecular:454.30BMS-986339
CAS:BMS-986339: oral, potent FXR agonist; binds to His298/ASN287; for PBC, PSC, NASH, anti-fibrosis research.Fórmula:C35H41F4N3O4Forma y color:SolidPeso molecular:643.71Danifexor
CAS:Danifexor is an agonist of the farnesoid X receptor (Farnesoid X receptor).Fórmula:C29H20Cl2N2O5Forma y color:SolidPeso molecular:547.386FXR agonist 12
CAS:FXR agonist12 (Compound C7) is an orally active FXR agonist. It downregulates bile acid synthesis-related genes and upregulates bile acid transport-related genes in HepG2 cells. FXR agonist12 alleviates ANIT-induced cholestasis and reduces liver damage and fibrosis in a mouse model of NASH.Fórmula:C26H44O3Forma y color:SolidPeso molecular:404.626FXR agonist 9
CAS:FXR agonist9 (compound 26) is a selective, orally active partial agonist of FXR with an EC50 of 0.09 µM (maximum efficacy of 75.13%). It ameliorates the pathological features of fatty liver disease in mice induced by HFD and CCl4-related metabolic dysfunction.Fórmula:C28H30N2O5Forma y color:SolidPeso molecular:474.55
